Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia
- 1 October 1987
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 60 (12) , G33-G42
- https://doi.org/10.1016/0002-9149(87)90589-3
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Lipid-Lowering DrugsDrugs, 1987
- Functional Activities of Hepatic Lipoprotein ReceptorsAnnual Review of Physiology, 1986
- Treatment of HypercholesterolemiaAnnual Review of Medicine, 1986
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.Journal of Clinical Investigation, 1983
- SUPERIORITY OF PARTIAL ILEAL BYPASS OVER CHOLESTYRAMINE IN REDUCING CHOLESTEROL IN FAMILIAL HYPERCHOLESTEROLAEMIAThe Lancet, 1981
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981
- COLESTIPOL PLUS NICOTINIC ACID IN TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIAThe Lancet, 1981
- Normalization of Low-Density-Lipoprotein Levels in Heterozygous Familial Hypercholesterolemia with a Combined Drug RegimenNew England Journal of Medicine, 1981
- Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activityFEBS Letters, 1976